Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRL-201 in Amyotrophic Lateral Sclerosis
NCT05633459Phase 1Active, not recruiting
- Sponsor
- QurAlis
- Start
- Dec 2022
- Primary completion
- May 2026
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of QRL-201 in amyotrophic lateral sclerosis (ALS) (5 arms), sponsored by QurAlis. Primary endpoint: Number of participants with one or more treatment emergent adverse events and serious adverse events at Day 421. Started Dec 2022; status: active, not recruiting.
02
Drugs
QRL-201
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05633459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633459.